• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
XIA Xuefei, ZHANG Li, LUO Jianhua, YAO Wenbing, GAO Xiangdong, TIAN Hong. Design and antitumor activity of immune checkpoint B7-H3 epitope vaccine[J]. Journal of China Pharmaceutical University, 2021, 52(4): 472-479. DOI: 10.11665/j.issn.1000-5048.20210410
Citation: XIA Xuefei, ZHANG Li, LUO Jianhua, YAO Wenbing, GAO Xiangdong, TIAN Hong. Design and antitumor activity of immune checkpoint B7-H3 epitope vaccine[J]. Journal of China Pharmaceutical University, 2021, 52(4): 472-479. DOI: 10.11665/j.issn.1000-5048.20210410

Design and antitumor activity of immune checkpoint B7-H3 epitope vaccine

Funds: This study was supported by the National Natural Science Foundation of China (No.81973222, No.82073754); Key Research and Development Project of and Xinjiang Autonomous Region (No.2020B03003-2)
More Information
  • Received Date: March 18, 2021
  • Revised Date: June 27, 2021
  • B7-H3 is an immune checkpoint molecule overexpressed on the surface of a variety of tumors, and is is an ideal target for tumor immunotherapy. In this study, nitrolated T cell epitope designed in the early stage of the laboratory was used to construct an epitope vaccine that can target immune checkpoint B7-H3. The vaccine can significantly inhibit tumor growth in the CT26 colon cancer model, and has a significant synergistic effect with the PD-L1 protein vaccine. B7-H3 vaccine can increase the proportion of CD4+ T cells in splenic T lymphocytes and the proportion of CD8+ T cells in tumor-infiltrating T lymphocytes, while reducing the proportion of suppressor Treg cells in tumor-infiltrating CD4+ T lymphocytes, which effectively improves tumor immunosuppressive microenvironment. Research results suggest that the B7-H3 epitope vaccine can be used as an effective tumor vaccine candidate molecule.
  • [1]
    . Clin Cancer Res,2016,22(14):3425-3431.
    [2]
    Kontos F,Michelakos T,Kurokawa T,et al. B7-H3:an attractive target for antibody-based immunotherapy[J]. Clin Cancer Res,2021,27(5):1227-1235.
    [3]
    Du H,Hirabayashi K,Ahn S,et al. Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells[J]. Cancer Cell,2019,35(2):221-237.
    [4]
    Leitner J,Klauser C,Pickl WF,et al. B7-H3 is a potent inhibitor of human T-cell activation:no evidence for B7-H3 and TREML2 interaction[J]. Eur J Immunol,2009,39(7):1754-1764.
    [5]
    Suh WK,Gajewska BU,Okada H,et al. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses[J]. Nat Immunol,2003,4(9):899-906.
    [6]
    Kang FB,Wang L,Li D,et al. Hepatocellular carcinomas promote tumor-associated macrophage M2-polarization via increased B7-H3 expression[J]. Oncol Rep,2015,33(1):274-282.
    [7]
    Mosser DM,Edwards JP. Exploring the full spectrum of macrophage activation[J]. Nat Rev Immunol,2008,8(12):958-969.
    [8]
    Mao Y,Chen L,Wang F,et al. Cancer cell-expressed B7-H3 regulates the differentiation of tumor-associated macrophages in human colorectal carcinoma[J]. Oncol Lett,2017,14(5):6177-6183.
    [9]
    Castriconi R,Dondero A,Augugliaro R,et al. Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis[J]. Proc Natl Acad Sci U S A,2004,101(34):12640-12645.
    [10]
    Castellanos JR,Purvis IJ,Labak CM,et al. B7-H3 role in the immune landscape of cancer[J]. Am J Clin Exp Immunol,2017,6(4):66-75.
    [11]
    Zhang Z,Jiang C,Liu Z,et al. B7-H3-targeted CAR-T cells exhibit potent antitumor effects on hematologic and solid tumors[J]. Mol Ther Oncolytics,2020,17:180-189.
    [12]
    Maeng H,Terabe M,Berzofsky JA. Cancer vaccines:translation from mice to human clinical trials[J]. Curr Opin Immunol,2018,51:111-122.
    [13]
    Wong KK,Li WA,Mooney DJ,et al. Advances in therapeutic cancer vaccines[J]. Adv Immunol,2016,130:191-249.
    [14]
    Tian H,He Y,Song X,et al. Nitrated T helper cell epitopes enhance the immunogenicity of HER2 vaccine and induce anti-tumor immunity[J]. Cancer Lett,2018,430:79-87.
    [15]
    Alexander J,Sidney J,Southwood S,et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides[J]. Immunity,1994,1(9):751-761.
    [16]
    Topalian SL,Drake CG,Pardoll DM. Immune checkpoint blockade:a common denominator approach to cancer therapy[J]. Cancer Cell,2015,27(4):450-461.
    [17]
    He Y,Tian H,Dai X,et al. Immunogenicity of HER2 vaccine containing p-nitrophenylalanine[J]. J China Pharm Univ(中国药科大学学报) ,2018,49(3):369-375.
    [18]
    Tian H,Kang Y,Song X,et al. PDL1-targeted vaccine exhibits potent antitumor activity by simultaneously blocking PD1/PDL1 pathway and activating PDL1-specific immune responses[J]. Cancer Lett,2020,476:170-182.
    [19]
    Sharma P,Allison JP. Immune checkpoint targeting in cancer therapy:toward combination strategies with curative potential[J]. Cell,2015,161(2):205-214.
    [20]
    Mahata B,Pramanik J,Van Der Weyden L,et al. Tumors induce de novo steroid biosynthesis in T cells to evade immunity[J]. Nat Commun,2020,11(1):3588.
    [21]
    Hendry S,Salgado R,Gevaert T,et al. Assessing tumor-infiltrating lymphocytes in solid tumors:a practical review for pathologists and proposal for a standardized method from the international immuno-oncology biomarkers working group:Part 2:TILs in melanoma,gastrointestinal tract carcinomas,non-small cell lung carcinoma and mesothelioma,endometrial and ovarian carcinomas,squamous cell carcinoma of the head and neck,genitourinary carcinomas,and primary brain tumors[J]. Adv Anat Pathol,2017,24(6):311-335.
    [22]
    Savage PA,Leventhal DS,Malchow S. Shaping the repertoire of tumor-infiltrating effector and regulatory T cells[J]. Immunol Rev,2014,259(1):245-258.
    [23]
    Stockis J,Roychoudhuri R,Halim TYF. Regulation of regulatory T cells in cancer[J]. Immunology,2019,157(3):219-231.
  • Related Articles

    [1]ZHU Song, JIANG Jing, LIU Yang, ZOU Wenyu, HU Pengwei, LU Yuting, SONG Min, HANG Taijun. Structural identification of the related substances of lorazepam tablets by LC-MS[J]. Journal of China Pharmaceutical University, 2021, 52(5): 555-565. DOI: 10.11665/j.issn.1000-5048.20210507
    [2]LIANG Fangmei, NI Yueling, WANG Lu, HANG Taijun, SONG Min. Structural identification of the related substances of fusidic acid by LC-MS[J]. Journal of China Pharmaceutical University, 2018, 49(3): 322-332. DOI: 10.11665/j.issn.1000-5048.20180311
    [3]YIN Xiaoya, WANG Cheng, MING Guojun, HANG Taijun. Identification of the related substances in pioglitazone hydrochloride by hyphenated LC-MS techniques[J]. Journal of China Pharmaceutical University, 2017, 48(6): 701-710. DOI: 10.11665/j.issn.1000-5048.20170611
    [4]XU Guijun, LI Zhijun, WANG Qi, TAN Jiejun, SHI Guoshan, QI Wei, LI Di, WANG Youpeng. Isolation and identification of anti-inflammatory constituents from Houttuynia cordata[J]. Journal of China Pharmaceutical University, 2016, 47(3): 294-298. DOI: 10.11665/j.issn.1000-5048.20160308
    [5]CHEN Wenhua, ZOU Limin, ZHANG Fei, ZHANG Liandi, LIAO Mingyi, DING Li. Identification of the related substances in bendamustine hydrochloride[J]. Journal of China Pharmaceutical University, 2015, 46(3): 333-338. DOI: 10.11665/j.issn.1000-5048.20150312
    [6]ZHOU Yongmei, SHI Xianming, MA Lei, ZHANG Sifang. Isolation and identification of Withaphysalins from Physalis minima[J]. Journal of China Pharmaceutical University, 2015, 46(1): 62-65. DOI: 10.11665/j.issn.1000-5048.20150107
    [7]RAO Ya-kun, DING Li, YU Yong. Structural identification of two major impurities in sodium levofolinate[J]. Journal of China Pharmaceutical University, 2012, 43(4): 350-354.
    [8]WANG Ying, YIN Hong-ping, CHEN Tao, WANG Min. Preliminary structural identification and protection on renal cell injury of acidic polysaccharide from Cordyceps sinensis[J]. Journal of China Pharmaceutical University, 2009, 40(6): 559-564.
    [9]Structure Studies of N-(4-chlorobenzyl)-2,3-methylenedio-xyl-9-acetoxyl-10-methoxy-7,8,13,13a-tetrahydro-8H-dibenzo-quinolizine chloride[J]. Journal of China Pharmaceutical University, 2002, (1): 72-74.
    [10]IDENTIFICATION OF SYNTHETIC BY-PRODUCT N-(4-CHLOROBENZOYL)-DICYCLOHEXANYLUREA BY FOURIER TRANSFORM MASS SPECTROMETRY[J]. Journal of China Pharmaceutical University, 1989, (6): 367-369.

Catalog

    Article views (212) PDF downloads (650) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return